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Metabolomics is thesystematic identificationandquantitationof allmetabolites inagivenorganismor
biological sample. The enhanced resolution provided by nuclear magnetic resonance (NMR) spec-
troscopy and mass spectrometry (MS), along with powerful chemometric software, allows the simul-
taneousdeterminationandcomparisonof thousandsof chemical entities,whichhas lead to anexpan-
sion of small molecule biochemistry studies in bacteria, plants, and mammals. Continued
development of these analytical platforms will accelerate the widespread use of metabolomics and
allow further integration of small molecules into systems biology. Here, recent studies using metab-
olomics in xenobiotic metabolism and genetically modified mice are highlighted.Before the advent of molecular medi-
cine, unraveling the mechanisms of
disease was essentially a biochemical
endeavor. The pioneering contribu-
tions of Sir ArchibaldGarrod in defining
the chemical nature of alkaptonuria in
1902 and Ivar Asbjørn Følling in uncov-
ering the underlying biochemical basis
of inherited impaired cognitive function
and development in 1934 relied solely
upon the systematic study of urine
constituents and of metabolism, using
methods that would be viewed as alien
today. Nevertheless, these studies
highlighted important concepts about
chemical individuality and led to simple
diagnostic tests, dietary interventions,
and treatments for these diseases. In
this current age ofmolecular medicine,
it is now within the reach of most labo-
ratories to investigate the structure and
functional expression of genomes on
a global scale. However, the study of
proteins at a global level, proteomics,
has not yet achieved such widespread
use. In contrast, metabolomics is
emerging as a field with tremendous
promise in extending ‘‘omics’’ from
the gene to the small molecule.
Metabolomics, the global metabolic
profiling of cells, tissues, or organisms
in relation to genetic variation or exter-
nal stimuli, is now sufficientlymature to
join the ranks of the other omics to
close the systems biology loop. Small
molecule biochemistry, the bedrock
of medical research for over a century,
is now reemerging from the shadows348 Cell Metabolism 6, November 2007 ªwhere it has been eclipsed by molecu-
lar genetics, reverse genetics, geno-
mics, proteomics, and other contem-
porary fields that bring with them
technologies of immense power and
insight. Via the rapid development of
metabolomics technology platforms
and by incorporating metabolomics
into research efforts, it is now possible
to answer key questions that could not
be fully addressed by the other omics
alone. From bacteria to humans, ex-
amples of this principle are accruing
at a rapid pace that has been made
possible by remarkable recent devel-
opments in analytical chemistry, such
as high-field nuclear magnetic reso-
nance (NMR) and mass spectrometry
(MS) platforms for small molecule sep-
aration, detection, and characteriza-
tion, together with the availability of
relatively user-friendly multivariate
data analysis software packages that
are able to deconvolute the huge data
matrices generated in a metabolomic
experiment. Such analysis of the
metabolome is being applied to an
ever-increasing number of biological
and medical research topics, from
bacteria to human.
One important area inwhichmetabo-
lomics is making a quintessential con-
tribution isprokaryoticgenomeannota-
tion. In the postgenomic age, it has
become apparent that at least 30%–
50% of genes in a newly sequenced
bacterial genome were incorrectly
annotated or are of unknown function2007 Elsevier Inc.(Siew et al., 2004). Indeed, the function
of one in five genes in the best under-
stood bacterial genome, E. coli, is
unknown (Liangetal., 2002). Smallmol-
ecule signatures could allow the func-
tion of these genes to be determined.
It has also recently become appar-
ent that the microbiota of the human
distal gut may play a key role in health
and disease. The collective genome of
these microorganisms contains at
least 100 times as many genes as our
own genome (Gill et al., 2006), and
data are beginning to emerge regard-
ing their role in human health (Ley
et al., 2006). A recent metabolomics
study harnessed both NMR and MS
technologies to compare normal gut
flora colonization in conventional
mice to human infant gut flora coloni-
zation in germ-free mice (Martin et al.,
2007). These authors suggested a role
of the microbiome in the absorption
and storage of lipids, as well as in the
extraction of energy from the diet.
They also proposed that manipulation
of the microbiome to produce ‘‘a bal-
anced and well-adapted microflora’’
may prevent certain human gastroin-
testinal and hepatic diseases (Martin
et al., 2007). In the future, if we are to
understand more fully the relationship
between dietary nutrients, dietary xe-
nobiotics, gut flora, and human health
and disease, it will be a priority to have
correct genomic annotations of the
main species of bacteria and archaea
that inhabit the human gut.
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ticular relevance to the health andwell-
being of humans. The metabolomes of
plants are unexpectedly complex, and
it has been estimated that some
200,000 molecules will eventually be
detected (Fiehn, 2002). Although the
complete genome of the well-studied
flowering plant Arabidopsis thaliana
has been sequenced, over 30% of its
genes are of unknown function, and
only 9% have been studied experi-
mentally (Seki et al., 2002), which calls
for a metabolomic approach for gene
annotation. Understanding metabolic
networks in plants has already deliv-
ered many important outcomes, such
as the detection of unintended effects
of geneticallymodified (GM) foodcrops
usinganunbiasedglobal screening ap-
proach instead of traditional targeted
metabolite detection, including expo-
sure to known toxins (Dixon et al.,
2006).
In mammals, the potential of meta-
bolomics is enormous, particularlywith
respect to studying the interface be-
tween our chemical universe and hu-
man biology. Humans are probably
exposed to some 1–3 million discrete
chemicals in our lifetimes, and most
of these xenobiotics are metabolized
in the body to render them less toxic.
However, in a significant number of
cases, the detoxication apparatus
renders a xenobiotic more chemically
reactive, potentially more toxic, and,
in some cases, carcinogenic. Under-
standing the role of human genetic dif-
ferences in xenobiotic metabolism and
its relationship to interindividual sus-
ceptibility to chemical toxicities and
carcinogenesis is an area of intense in-
terest (Wogan et al., 2004). A conve-
nient, cost-effective means to deter-
mine metabolic potential would be of
great value in understanding the mo-
lecular epidemiology of cancer and is
an area in which metabolomics can
be brought to bear. In addition, drug-
induced toxicities have a major impact
on the clinical use of drugs, and the
pharmaceutical industry has sought
to develop methods to predict the po-
tential adverse effects of compounds
early in drug development. For this rea-
son, metabolomics is being developed
as a platform to study and predict drug
toxicities during preclinical drug devel-opment. After administration of a drug,
urinary metabolites can serve as a fin-
gerprint for organ-specific toxicities,
thus potentially eliminating the need
for laborious pathological analysis of
tissuesandenhancing throughput (Lin-
don et al., 2007).
Another area of drug development in
which metabolomics can have a major
role is pharmacogenetics, the study of
person-to-person variability in drug
metabolism and toxicity. Genetic dif-
ferences in drug metabolism have his-
torically been studied in clinical phar-
macology by direct genotyping for
known variant alleles of genes that en-
code drug-metabolizing enzymes and
transporters. For a more global analy-
sis of interindividual variation in me-
tabolism and susceptibility to toxicity,
metabolomics can be employed. A
proof-of-principle study in an animal
model revealed the potential for
metabolomics profiling in predicting
responses to drugs (Clayton et al.,
2006). However, it remains to be deter-
mined whether this approach can be
translated to humans due to large
interindividual variations in the urinary
metabolome, resulting from genetic
and dietary diversity.
Recently, the use of transgenic
mouse lines has yielded important re-
sults to better understand pathways
that lead to drug and chemical toxicity,
drug-drug interactions, mechanisms
of carcinogenesis, and the role of me-
tabolism in cancer chemotherapy as
well as to develop precise biomarkers
that can be translated to humans. In
all of these areas, the unique combina-
tion of transgenic mouse generation
andmetabolomic analysis is furnishing
answers to important questions rele-
vant to human health and disease.
For example, metabolomic technol-
ogy, in particular the power of multi-
variate analysis of liquid chromatogra-
phy-mass spectrometry (LC-MS) data,
has been applied in combination with
cytochrome P450 (a gene important
in xenobiotic detoxication, among
other functions) knockout mice to re-
veal a fuller panoply of the metabolites
of the ubiquitous dietary carcinogen 2-
amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP), revealing 17 urinary
metabolites, 8 of which were novel
(Chen et al., 2007). PhIP, a suspectedCell Metabolism 6,human dietary carcinogen, is of poten-
tial importance as a food mutagen
found in overcooked and pan-fried
meats. Use of CYP1A2-humanized
mice has demonstrated that the hu-
man CYP1A2 is far more active than
the corresponding mouse enzyme in
producing a metabolite that ultimately
leads to the DNA-binding derivative
of the carcinogen. Similarly, by carry-
ing out a metabolomic study on mice
given the experimental anticancer
drug aminoflavone, 13 mouse urinary
metabolites were observed, 12 of
which were novel (Chen et al., 2006).
The use of CYP1A2-humanized mice
revealed an important species differ-
ence in the metabolism of aminofla-
vone (Chen et al., 2006). It is conceiv-
able that similar studies, aimed at
assessing human-specific genetic dif-
ferences in metabolism, could be per-
formed in drug-treated humans.
Metabolomics can be used to find
molecular fingerprints for gene defi-
ciency and activation of nuclear recep-
tors. For example, molecular finger-
prints have been uncovered in urine
for both the presence of an active nu-
clear receptor, peroxisome prolifera-
tor-activated receptor a (PPARa), and
the activation of PPARa by its ligands
(Zhen et al., 2007) (Figure 1A). While
metabolic alterations would be ex-
pected upon ligand activation, quite
surprisingly, a number of changes in
levels of metabolites were noted in
the absence of PPARa. Using these
data, metabolites can be found that
distinguish between groups, and these
metabolites can then serve as bio-
markers for PPARa expression and
activation. The differences between
genotypes can also be visualized by
novel software that displays the global
differences in the urinary metabolome
between Ppara+/+ and Ppara/ mice
(Figure 1B). One of the principal find-
ings of the PPARa metabolomics
study was that novel steroid metaboli-
tes of unknown function were highly
elevated upon ligand activation of
PPARa (Zhen et al., 2007).
Metabolomics also holds great
promise for the discovery of chemical
biomarkers for diseases that are ame-
nable to measurement by urine analy-
sis. Indeed, 1H-NMR analysis of hu-
man serum has been used to searchNovember 2007 ª2007 Elsevier Inc. 349
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(A) Metabolomics analysis of ligand-treated and untreated wild-type (+/+) and Ppara null (/)
mice by ultra-performance liquid chromatography/time-of-flight mass spectrometry. Left panel:
principal components analysis (PCA) scores plot of principle component 1 versus principle com-
ponent 2 for four groups of mice, wild-type and Ppara null mice both untreated and treated with
Wy-14,643, a PPARa agonist ligand. Right panel: PCA scores plot of component 1 versus compo-
nent 2 for two groups of mice, untreated wild-type and Ppara null mice. Note that the treated and
untreated null mice cluster together.
(B) Analyses and visualization of patterns inMS datamatrices. Self-organizingmaps showing a ho-
listic view of the mouse urinary metabolome for groups of male C57BL/6 mice with Ppara+/+ and
Ppara/ genotypes. Maps were constructed using Gene Expression Dynamics Inspector (GEDI)
software (Guo et al., 2006) and published data (Zhen et al., 2007). Each tile comprises a group of
metabolites that covary across the whole data set, on average 12. Dark blue is the lowest intensity
of metabolites; dark red is the highest intensity. The two urinary biomarkers for the Ppara+/+ geno-
type that we have reported (Zhen et al., 2007), 2,8-dihydroxyquinoline and xanthurenic acid, are
both located in the bottom right tiles and are thus in the region that is considerably elevated by
the presence of the Ppara gene. Figure 1B kindly provided by A. Patterson (Laboratory of Metab-
olism, Center for Cancer Research, NCI, NIH).for chemical signatures of coronary
artery disease (Brindle et al., 2002).
This task is quite daunting due to the
genetic differences, dietary diversity,
and other problems inherent in the hu-
man population that lead to marked in-
terindividual differences in the human
serum metabolome. While these diffi-
culties can be overcome by studying
large populations of cases and con-
trols with powerful statistical multivari-
ate data analysis software that is able
to mine large data sets, a better delin-
eated approach may be the use of
animal disease models to identify can-
didate biomarkers that can then be val-350 Cell Metabolism 6, November 2007 ªidated in humans. Biomarkers that can
be used to diagnose prediabetes, can-
cer, and coronary artery disease would
be of great value in clinical medicine.
As has been discussed, metabolo-
mics is playing a unique role in the
systems biological study of health, dis-
ease, theenvironment, andagriculture.
Small molecule biochemistry, rele-
gated to a lesser role over the past
two decades by genomics, transcrip-
tomics, and proteomics, is now under-
going a renaissance of sorts. With the
advent of high-end chemical analytical
instrumentation, combined with che-
mometric analysis of the data-rich out-2007 Elsevier Inc.puts, small molecule biochemistry is
now fully integrated with the other
omics to more fully complete systems
biology. While we fully expect that me-
tabolomics will find a place in all as-
pects of biological and medical re-
search, its contributions could be
accelerated by the development of
quantum leap technologies. At pres-
ent, due to their diverse physical prop-
erties, the global profiling of small mol-
ecules requires multiple analytical
platforms, including NMR and a range
of MS technologies, in order to gain
maximum coverage of the metabo-
lome. This situation, requiring many in-
struments, is cumbersome. We look
forward to a day when metabolomic
analysis that can capture the whole
metabolome is truly accessible and
widely available in the way that PCR,
SNPmapping, andmicroarray analysis
arenow.Thiswill requireacommitment
of the best minds in academic re-
search, as well as a willingness of in-
dustrial manufacturers to fulfill the col-
lective vision of a world with simple,
cheap, and reproducible metabolomic
profiling, a true electronic dog’s nose.
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